Trials / Completed
CompletedNCT00132652
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
A Randomized Trial of Switching Antiviral Therapy From Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults With Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine (LdT) against continued lamivudine treatment. Results from patients who were taking lamivudine and then switched to telbivudine will be compared with the results from patients who continued on lamivudine alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lamivudine | |
| DRUG | Telbivudine |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2005-08-22
- Last updated
- 2017-02-23
Locations
14 sites across 11 countries: United States, Australia, Canada, China, France, Israel, New Zealand, Singapore, Taiwan, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00132652. Inclusion in this directory is not an endorsement.